You are currently viewing a new version of our website. To view the old version click .
Toxics
  • Editor’s Choice
  • Systematic Review
  • Open Access

18 May 2022

Towards Reference Values for Malondialdehyde on Exhaled Breath Condensate: A Systematic Literature Review and Meta-Analysis

,
,
,
,
,
and
1
Center for Primary Care and Public Health (Unisanté), University of Lausanne, Route de la Corniche 2, 1066 Epalinges, Switzerland
2
Department of Public Health and Pediatrics, University of Turin, Via Zuretti 29, 10125 Turin, Italy
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
This article belongs to the Special Issue Human Biomonitoring in Health Risk Assessment: Current Practices and Recommendations for the Future

Abstract

Many pathological conditions and certain airway exposures are associated with oxidative stress (OS). Malondialdehyde (MDA) is an end-product of the oxidation of lipids in our cells and is present in all biological matrices including exhaled breath condensate (EBC). To use MDA as a biomarker of OS in EBC, a reference interval should be defined. Thus, we sought to summarize reference values reported in healthy adult populations by performing a systematic review and meta-analysis using a standardized protocol registered in PROSPERO (CRD42020146623). Articles were retrieved from four major databases and 25 studies with 28 subgroups were included. Defining the distribution of MDA measured in reference populations with a detection combined with a separation technique still represents a challenge due to the low number of studies available, different analytical methods used, and questionable methodological qualities of many studies. The most salient methodological drawbacks have been in data collection and reporting of methods and study results by the researchers. The lack of compliance with the recommendations of the European Respiratory Society and American Thoracic Society was the major limitation in the current research involving EBC. Consequently, we were unable to establish a reference interval for MDA in EBC.

1. Introduction

Oxidative stress is an imbalance between production and elimination of reactive oxygen species (ROS), and represents a common pathological pathway for many inflammatory diseases, including chronic and acute lung conditions, such as chronic obstructive disease and asthma [1]. The biological effects of excess ROS production are their interactions with membrane lipids, a process known as lipid peroxidation, which yields a series of secondary molecules capable of exacerbating the oxidative damage [2]. Malondialdehyde (MDA) is one of the end-products of lipid peroxidation and has been largely investigated as a biomarker of oxidative stress. MDA correlates with different pathological states, such as cardiovascular disease and atherosclerosis [3,4], diabetic disease [5], Alzheimer’s, DNA damage, and ageing [6]. MDA has also been extensively investigated as a biomarker of pulmonary oxidative stress [7] and in evaluating the impact of air pollution, smoking [8], or respiratory exposure in occupational environments such as exposure to heavy metals [9] and particles [10].
MDA has attracted attention and interest as a biomarker of oxidative stress, because it can be detected in a variety of biological matrices, i.e., blood, urine, and exhaled breath condensate (EBC), and has shown good correlations with other biomarkers of lipid peroxidation [11].
EBC, the biological matrix considered in this meta-analysis, can be obtained by cooling an individual’s exhaled air using a noninvasive and safe procedure. This condensate contains low-volatile compounds and aerosolized airway lining fluid [12] which have been diluted by water [13]. According to current recommendations from the joint task force of American Thoracic Society and European Respiratory Society, EBC collection can be performed by asking an individual to breathe normally into a tube connected to a cooling apparatus while wearing a nose clip for a period of time until a reasonable amount of condensate is collected [14]. The current ERS technical standards also include specific recommendations as follows: (a) define and report EBC volume, time of collection, collection temperature, breathing pattern, prevention of salivary and environmental contamination, ambient conditions; (b) keep the time between collection of EBC and analysis as short as possible; (c) report results in terms of concentration per 100l of EBC or per minute, in order to reduce the confounding factor of the dilution of substances in the EBC; (d) report data concerning the intra- and inter-assay variability, limit of detection, sensitivity of detection methods, and more generally describe the methods and techniques used to collect and analyze the EBC; (e) note and report the time between food intake and EBC collection; (f) schedule collection for the same time of day.
The same task force, in 2005, also released a first series of methodological recommendations which were more generic than the 2017 recommendations, and the use of a nose clip and a saliva trap have been formulated since the earlier version. The biomarkers in EBC originate from different regions of the respiratory tract, from the lower airways and lungs up to the oropharynx and nasopharynx [15]. Hence, the use of a nose clip is recommended to prevent collection of mediators formed in the nose and the sinuses and to exclusively collect from the lower airways, as well as to ensure that no sample is lost through nasal respiration [16]. Similarly, saliva contamination needs to be avoided since it may contain the same mediators of interests but derived from other anatomical sites than the lower respiratory zone. It has been proposed that a saliva trap is sufficient, since there is a need for a sensitive test for salivary alpha-amylase.
Other recommendation in the 2005 version included performing the analysis as soon as possible after collection, noting and reporting temperature collection, and detailing the collection devices if custom materials are used especially for the contact surface. Although a collection time of 10 min has been recommended, further research on the effect of collection time and temperature versus expiratory volume is needed [17]. Concerning the collection and analysis methods, the 2005 ATS/ERS recommendations were to provide sufficient details to ensure the reproducibility of technique.
Furthermore, reporting participants’ details, such as smoking habits, race, age, sex, as well as eating and drinking behaviors have also been recommended since the first version of the task force [14]. We found it crucial to detail these two series of recommendations from the joint task force of the American Thoracic Society and European Respiratory Society, as this could have affected the different study protocols in the studies reviewed for this meta-analysis.
MDA concentrations in EBC are usually quantified after collection and storage at low temperatures for up to 6 months, by using different analytical and separation methods: high performance liquid chromatography (HPLC) coupled with mass spectrometry (MS) or UV photometry detection. MDA is derivatized with either thiobarbitoric acid (TBA) or 2,4-dinitrophenylhydrazine (DNPH), with TBA being less specific for MDA [18].
Different levels of MDA in the EBC have been detected in some physiological or pathological conditions characterized by oxidative stress, but the absence of established or recognized reference intervals has limited the interpretation of the findings of the MDA as a biomarker in different settings. Thus, the current research has as a primary objective to investigate the possibility of defining reference intervals for MDA in EBC.

2. Materials and Methods

The present study focuses on MDA measured in EBC and is part of a series of systematic reviews and meta-analyses for several oxidative stress biomarkers in two different matrices: urine and EBC [19].
Our protocol followed recommendations from the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) [20] and is registered with the International Prospective Register of Systematic Reviews (PROSPERO, registration number CRD 42020146623) [21].

2.1. Literature Research

Research for scientific literature was conducted on four different databases (The Cochrane Central Register, EMBASE, PubMed, and Web of Science), from journal apparition up to October 2020. We performed a quick search for the period covering the end of 2020 to end of 2021 to confirm that no new data had been published that could change our outcome. The research string was constructed in collaboration with the library of Unisanté and their documentarist using a combination of Medical Subject Headings (MeSH) terms and key words. The complete research string has been described elsewhere (www.doi.org/10.16909/dataset/17, accessed on 15 February 2022) and is available at the Unisanté data repository.

2.2. Study Selection

We included only original research studies written in English that reported MDA concentrations in EBC among human healthy adults. The flowchart in Figure 1 represents the selection process of the studies that were ultimately included in our meta-analysis. First, we identified and excluded duplicates, and second, we used the Rayyan software [22] for title and abstract screening.
Figure 1. Flowchart of the article selection process.
The exclusion criteria were: MDA measured in any other matrix than EBC (e.g., blood/plasma and sperm) in vitro or non-human studies (animal or plant), incorrect MDA abbreviation (e.g., mass drug administration and methylenedioxyamphetamine), and inappropriate types of publications such as reviews or conference papers. In accordance with our registered protocol, our research string was built to cover an entire series of OS biomarkers, and was not limited to MDA. Consequently, our initial pool of articles contained articles that did not refer to MDA. Another factor that made this pool large was that authors often chose keywords that were very generic such as “oxidative stress” and “biomarkers of oxidative stress”.

2.3. Data Extraction

We extracted data according to a previously published protocol [19], including a list of parameters regarding technical aspects of the analytical methods used to measure MDA in EBC and lifestyle factors such as body mass index (BMI) and vitamin supplement intake. We only extracted data on healthy subjects who were free of any disease, especially inflammatory conditions, and who were free of known inhalation exposure, or, where possible, who were healthy subjects before an exposure, i.e., baseline data and, if possible, all subgroup-specific data.

2.4. Quality Assessment

Articles that underwent data extraction were also evaluated using a standardized quality assessment checklist, previously used in other studies [22]. This allowed us to appraise four different domains: study design and risk of bias, technical and analytical methods, study sample, and data interpretation. We assessed different criteria for each domain and graded them with scores from 1 to 3. The output was an overall score ranging from 0 to 27. In this range, two cut-offs and three quality categories were established: “low” (scores less than or equal to ≤9), “moderate” (scores less than or equal to ≤18), and “high” (scores greater than 19). The checklist used to perform the quality assessment is detailed in Supplementary Table S1 and the overall scores of articles elected for data extraction are listed in Table 1.
Table 1. Qualitative synthesis of articles that underwent data extraction.

2.5. Statistical Analysis

We computed geometric means (GMs) and geometric standard deviations (GSDs) as the basis of the meta-analysis. For value conversion and unit harmonization, we used different formulae according to types of data available and as previously described in [63].
Regarding the meta-analysis itself, the first step involved estimating the geometric means (GMs), and then representing the data with forest plots since they illustrated the heterogeneity and the overall combined results from individual studies. Between-study heterogeneity was evaluated with a Q test and displayed for each category in the forest plots. Finally, we modeled the Log-transformed GMs using linear models. We reported the results in ng/mL of MDA in EBC.

3. Results

Among the 40 full-text articles from which we extracted the data, several studies had to be excluded due to statistical errors such as lack of variability estimates or impossible reported ranges for the studied groups. We also excluded from the meta-analysis several study groups that demonstrated a coefficient of variation (CV), either <20% or >200%. The former corresponds to the analytical variability alone, and implies no between-subject variability. The latter implies that the study is uninformative. One study was excluded as the results had been reported using inappropriate units. The whole selection process is illustrated in Figure 1.
Since different factors were indicated as potential confounding factors in the literature, we wanted to assess their influence. Therefore, the results were stratified by gender, age, smoking status, EBC collection device, duration of EBC collection, use of nose clip, and analytical methods combined with their detection methods. We created a separate group identified by the abbreviation NA, meaning “not available”, which was assigned when the information was not given in the article. This resulted in the description of 28 study subgroups. Figure 2 shows the boxplots concerning the collection device (Figure 2a), duration of collection (Figure 2b), and gender groups (Figure 2c).
Figure 2. MDA concentration in EBC stratified according to: (a) Collection device; (b) duration of collection (minutes); (c) gender group (no papers with females only). All presented results exclude the outliers and units of the GMs are ng/mL.
Among the included articles, we identified the following analytical and separation methods combined with a derivatizing agent: high-performance liquid chromatography/thiobarbituric acid HPLC/TBA, spectrophotometry/TBA, HPLC—mass spectroscopy, HPLC-MS/initrophenylhydrazine (DNPH), and HPLC without mentioning the derivatizing agent and detection technique. A mixed effect regression analysis was performed to verify differences among the MDA GMs measured by different analytical methods. The same was done concerning the use of a nose clip versus no use of a nose clip, age categories, and among smokers and non-smokers. For each category, a factor-specific Wald test within the model was equally performed. Table 2 shows the results of the mixed-effects regression analysis. As compared with MDA GMs measured in EBC by HPLC/TBA, which was considered to be the reference method, the MDA GMs measured by MS/DNPH were significantly lower. The GMs of EBC MDA collected in uncertain conditions were higher as compared with the GMs of EBC collected while wearing a nose clip, which was the reference group. GMs of MDA in EBC higher than the reference were also found in smokers and in subjects 50+ years old as compared with in subjects younger than 30 years old.
Table 2. Mixed effects regression analysis according to analytical method, use of nose clip, smoking status, and age category.
These results were equally presented as separate forest plots, which better illustrate the heterogeneity for the age categories (Figure 3) and smoking habits (Figure 4).
Figure 3. Forest plots of MDA in EBC concentration quantified in healthy adult participants by age group: population with a mean age less than 30 years [28,43,46,58]; between 30 and 40 years [25,31,34,41,42,49,51,59], between 40 and 50 years [32,36,55] and above 50 years [24,26,36,46,50].
Figure 4. Forest plots of MDA in EBC concentration quantified in healthy adult participants considering their smoking habits: non-smokers exclusively [24,25,31,32,34,36,42,43,46,50,58]; mixed population of smokers and non-smokers [41,49,55], smokers exclusively [24,26,36,46,51] and unknown smoking status [28,44,59].
The predicted GMs in ng/mL for MDA measured in EBC is provided in Table 3, as well as the 95% confidence interval for each parameter considered. We observe that most of our predicted values fall in the interval of 0.18–2.87 ng/mL.
Table 3. Predicted concentrations of MDA (ng/mL) in EBC using the linear model.

4. Discussion

This meta-analysis showed that subjects older than 50 years had different MDA in EBC values from those younger than 30 years of age. Hence, for healthy subjects aged 30–50 years, we observed MDA in EBC values ranging from 0.18 to 2.87 ng/mL. Another observation we made was that smokers had higher values, almost double, of MDA in EBC as compared with non-smokers.
These findings are in line with recent studies that have investigated the link between aging and oxidative stress and have demonstrated the age dependence of oxidative stress in humans, although on different matrices. When measuring several biomarkers of oxidative stress, Pinchuk et al. revealed that MDA increased with age, and especially in post-menopausal women [63], and they attributed this to changes in estrogen levels. A meta-analysis regarding urinary MDA has made similar findings, that is, a trend of MDA values increasing with age, probably through the pathway of proteasome dysfunction. In addition, the association between smoking and increased oxidative stress has been well established, i.e., smoking induces the production of reactive oxygen species (ROS) that may activate a cascade and generate further molecular damage [64]. Although limited, there is evidence that MDA also increases in the EBC of smokers and not just in biological matrices such as the blood [65].
Our meta-analysis revealed significant variations in MDA levels according to the use of a nose clip during the EBC collection. The interpretation of such a finding is flawed by the inclusion of studies that did not specify if they used the nose clip or not. The finding itself would be coherent with the present recommendations to use a nose clip.
Nevertheless, we do not suggest the above-mentioned value intervals as reference intervals, due to several factors, which are discussed in the following paragraphs, such as the high heterogeneity, the low number of studies, or the use of proximity samples in the majority of the selected studies.

4.1. Heterogeneity

Our meta-analysis had a high level of heterogeneity, which we failed to reduce in subgroup analysis. This may be due to several factors, such as the heterogeneity in several steps: sample collection, chemical analytical analysis, data collection, and data reporting. Missing information regarding these steps also led to mitigated quality scores, mostly being moderate to low (Table 1).

4.1.1. Heterogeneity Related to the Collection of EBC

We checked the compliance with current methodological recommendations for EBC collection according to the date of article publication, and found three studies performed after 2017; two of these studies respected the guidelines concerning the EBC collection. The majority of the 26 studies included in the qualitative analysis was published between 2005 and 2017. Even though these studies should have adhered to the ERS/ATS 2005 recommendations, ten studies stated that they did not use a nose clip or did not provide the information regarding the use of a nose clip. The reasons for omitting this information or for not providing a nose clip to the participants as recommended by the guidelines remain to be unclear. Similar observations were made concerning the EBC devices, collection duration, and time of day the EBC collection was performed. Further, for about a fourth of the studies, we did not have enough information from the published article to allow us to understand if saliva contamination had been excluded.

4.1.2. Heterogeneity Related to the Analytical Method

Studies in our meta-analysis reported the use of different MDA derivation methods. The authors presented improved or modified already existing methodologies, which probably contributed to the overall heterogeneity. Moreover, data concerning the limit of detection and/or the limit of quantification, exclusion of potential contamination, and parameters of transportation or storage were partially revealed in the articles.

4.1.3. Heterogeneity Related to Data Collection and Reporting

Concerning the data collection and reporting, almost 20% of the studies did not specify the distribution of males and females among their control participants, 25% of the studies did not clearly report the smoking status, and 60% of the studies did not provide information on the BMI. Ideally, in addition to these basic data, more information concerning lifestyle factors and dietary information, such as vitamin intake, medical regime, occasional drug use, or living in an area with traffic-related heavy air pollution, should be taken into consideration, to better study their influence on MDA levels [66]. As these factors might influence the level of MDA in a reference sample, MDA reference intervals should be stratified accordingly, avoiding any misleading estimation.

5. Study Strengths and Limitations

The strengths of our meta-analysis are our rigorous research protocol, the exhaustive literature search by a documentarist using four databases, and our effort to harmonize units and generate background values as geometric means. Given the time lapse between literature research and data extraction, we also checked for studies published after October 2020, but this did not change our dataset.
Nevertheless, in this meta-analysis, the reduced number of performed studies and their quality represented major limitations. Ultimately, this also led to the high overall heterogeneity, which we did not manage to reduce even by performing a subgroup analysis.

6. Recommendations

Good quality and complete datasets are required to derive a reference interval of MDA in the EBC; however, the heterogeneity among studies observed here, prompts us to strongly recommend that researchers collect and report complete data information in future studies. This pertains especially to:
(a)
Collection and reporting of demographics and health status, namely gender, age, smoking status, BMI, diet, living area, sports, and respiratory functions to insure that the study sample does really correspond to the reference sample, and that it is representative of the general healthy population and all its subgroups.
(b)
Collection and reporting of the time of EBC collection and volume of collected EBC as this is one ERS/ATS recommendation that has not yet been fulfilled. We strongly recommend avoiding the use of non-validated EBC collection devices since it has been shown that the inner surface of the collection equipment can interfere with the determination of biomarkers [67], presumably, also with MDA determination. Therefore, EBC collections need to be standardized. A greater number of studies respecting the current guidelines would help to get closer to establishing a standardized EBC collection method.
(c)
Reporting of analytical methods that may affect MDA quantification and other factors influencing or supposed to influence the results, related to the analysis itself or collection device and material.

7. Conclusions

Our systematic review and meta-analysis could not provide any reference interval for MDA in EBC, due to the large heterogeneity among studies and the methodological limitations encountered. Further research is needed to, first, understand the influence of demographic and collection parameters on the MDA values in EBC, and secondly, to harmonize analytical methods. This and a sufficient number of high-quality studies would help to define MDA reference values in EBC.

Supplementary Materials

The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/toxics10050258/s1, Supplementary Table S1: Quality assessment criteria. References [22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61] are cited in the supplementary materials.

Author Contributions

The manuscript was written by V.T. and revised by all authors; N.B.H. and I.G.C. conceptualized and designed the study; M.H. initiated the research protocol; V.T. extracted and screened the studies; J.-J.S. served as an advisor for the manuscript and technic information; E.B. served as an advisor for the manuscript drafts; P.W. performed all statistical analyses. All authors have read and agreed to the published version of the manuscript.

Funding

This study was conducted within the framework of the EU Life Project “NanoExplore” (grant no. LIFE17ENV/GR/000285) and the Franco-Swiss project “ROBoCoP” (Swiss National Science Foundation grant no IZCOZ0_177067).

Institutional Review Board Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

  1. Borrill, Z.L.; Roy, K.; Singh, D. Exhaled breath condensate biomarkers in COPD. Eur. Respir. J. 2008, 32, 472–486. [Google Scholar] [CrossRef] [PubMed]
  2. Repetto, M.; Semprine, J.; Boveris, A. Lipid Peroxidation: Chemical Mechanism, Biological Implications and Analytical Determination. In Lipid Peroxidation; Catala, A., Ed.; InTech: London, UK, 2012; Available online: http://www.intechopen.com/books/lipid-peroxidation/lipid-peroxidation-chemical-mechanism-biological-implications-and-analytical-determination (accessed on 19 October 2021).
  3. Ito, F.; Sono, Y.; Ito, T. Measurement and Clinical Significance of Lipid Peroxidation as a Biomarker of Oxidative Stress: Oxidative Stress in Diabetes, Atherosclerosis, and Chronic Inflammation. Antioxidants 2019, 8, 72. [Google Scholar] [CrossRef] [PubMed]
  4. Cherubini, A.; Ruggiero, C.; Polidori, M.C.; Mecocci, P. Potential markers of oxidative stress in stroke. Free. Radic. Biol. Med. 2005, 39, 841–852. [Google Scholar] [CrossRef]
  5. Cvetković, T.; Mitić, B.; Lazarević, G.; Vlahović, P.; Antić, S.; Stefanović, V. Oxidative stress parameters as possible urine markers in patients with diabetic nephropathy. J. Diabetes Its Complicat. 2009, 23, 337–342. [Google Scholar] [CrossRef]
  6. Jové, M.; Mota-Martorell, N.; Pradas, I.; Martín-Gari, M.; Ayala, V.; Pamplona, R. The Advanced Lipoxidation End-Product Malondialdehyde-Lysine in Aging and Longevity. Antioxidants 2020, 9, 1132. [Google Scholar] [CrossRef] [PubMed]
  7. Del Rio, D.; Stewart, A.J.; Pellegrini, N. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr. Metab. Cardiovasc. Dis. 2005, 15, 316–328. [Google Scholar] [CrossRef]
  8. Kostikas, K.; Minas, M.; Nikolaou, E.; Papaioannou, A.I.; Liakos, P.; Gougoura, S.; Gourgoulianis, K.I.; Dinas, P.C.; Metsios, G.S.; Jamurtas, A.Z.; et al. Secondhand smoke exposure induces acutely airway acidification and oxidative stress. Respir. Med. 2013, 107, 172–179. [Google Scholar] [CrossRef]
  9. Denise, G.; Santa, M.L.; Juliana, V.; Clóvis, P.; Cristina, S.G.G.S.; Pomblum; Juarez, V.; Rocha, J.B.T.; Marcelo, F. Importance of the lipid peroxidation biomarkers and methodological aspects FOR malondialdehyde quantification. Quim. Nova 2009, 32, 169–174. [Google Scholar]
  10. Sauvain, J.J.; Edmé, J.L.; Wild, P.; Suarez, G.; Bezerra, O.M.P.A.; Talvani, A.; Algranti, E.; Carneiro, A.P.S.; Chérot-Kornobis, N.; Sobaszek, A.; et al. Does exposure to inflammatory particles modify the pattern of anion in exhaled breath condensate? J. Breath Res. 2020, 14, 026005. [Google Scholar] [CrossRef]
  11. Gaggini, M.; Sabatino, L.; Vassalle, C. Conventional and innovative methods to assess oxidative stress biomarkers in the clinical cardiovascular setting. Biotechniques 2020, 68, 223–231. [Google Scholar] [CrossRef]
  12. Hunt, J. Exhaled breath condensate: An evolving tool for noninvasive evaluation of lung disease. J. Allergy Clin. Immunol. 2002, 110, 28–34. [Google Scholar] [CrossRef] [PubMed]
  13. Davis, M.D.; Montpetit, A.; Hunt, J. Exhaled Breath Condensate: An overview. Immunol. Allergy Clin. N. Am. 2012, 32, 363–375. [Google Scholar] [CrossRef] [PubMed]
  14. Horváth, I.; Barnes, P.J.; Loukides, S.; Sterk, P.J.; Högman, M.; Olin, A.C.; Amann, A.; Antus, B.; Baraldi, E.; Bikov, A. A European Respiratory Society technical standard: Exhaled biomarkers in lung disease. Eur. Respir. J. 2017, 49, 1600965. [Google Scholar] [CrossRef] [PubMed]
  15. Davis, M.D.; Montpetit, A.J. Exhaled Breath Condensate: An update. Immunol. Allergy Clin. N. Am. 2018, 38, 667–678. [Google Scholar] [CrossRef] [PubMed]
  16. Latzin, P.; Beck, J.; Bartenstein, A.; Griese, M. Comparison of exhaled breath condensate from nasal and oral collection. Eur. J. Med Res. 2003, 8, 505–510. [Google Scholar] [PubMed]
  17. Horváth, I.; Hunt, J.; Barnes, P.J. Exhaled breath condensate: Methodological recommendations and unresolved questions. Eur. Respir. J. 2005, 26, 523–548. [Google Scholar] [CrossRef] [PubMed]
  18. Forman, H.J.; Augusto, O.; Brigelius-Flohe, R.; Dennery, P.A.; Kalyanaraman, B.; Ischiropoulos, H.; Mann, G.E.; Radi, R.; Roberts, L.J.; Vina, J. Even free radicals should follow some rules: A Guide to free radical research terminology and methodology. Free. Radic. Biol. Med. 2015, 78, 233–235. [Google Scholar] [CrossRef]
  19. Hemmendinger, M.; Wild, P.; Shoman, Y.; Graille, M.; Bergamaschi, E.; Hopf, N.; Guseva Canu, I. Reference ranges of oxidative stress biomarkers selected for non-invasive biological surveillance of nanotechnology workers: Study protocol and meta-analysis results for 8-OHdG in exhaled breath condensate. Toxicol. Lett. 2020, 327, 41–47. [Google Scholar] [CrossRef]
  20. Liberati, A.; Altman, D.G.; Tetzlaff, J.; Mulrow, C.; Gøtzsche, P.C.; Ioannidis, J.P.A.; Clarke, M.; Devereaux, P.J.; Kleijnen, J.; Moher, D. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration. PLoS Med. 2009, 6, e1000100. [Google Scholar] [CrossRef]
  21. Shoman, Y.; Wild, P.; Hemmendinger, M.; Graille, M.; Sauvain, J.J.; Hopf, N.B.; Guseva Canu, I. Reference Ranges of 8-Isoprostane Concentrations in Exhaled Breath Condensate (EBC): A Systematic Review and Meta-Analysis. Int. J. Mol. Sci. 2020, 21, 3822. [Google Scholar] [CrossRef]
  22. Ouzzani, M.; Hammady, H.; Fedorowicz, Z.; Elmagarmid, A. Rayyan—A web and mobile app for systematic reviews. Syst Rev. Déc 2016, 5, 210. [Google Scholar]
  23. Aksu, K.; Kurt, H.; Gündüz, E.; Değirmenci, I.; Kurt, E. Inflammatory markers in exhaled breath condensate in patients with asthma and rhinitis. Tuberk Toraks 2012, 60, 321–326. [Google Scholar]
  24. Andreoli, R.; Manini, P.; Corradi, M.; Mutti, A.; Niessen, W.M.A. Determination of patterns of biologically relevant aldehydes in exhaled breath condensate of healthy subjects by liquid chromatography/atmospheric chemical ionization tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2003, 17, 637–645. [Google Scholar] [CrossRef] [PubMed]
  25. Antus, B.; Drozdovszky, O.; Barta, I.; Kelemen, K. Comparison of Airway and Systemic Malondialdehyde Levels for Assessment of Oxidative Stress in Cystic Fibrosis. Lung 2015, 193, 597–604. [Google Scholar] [CrossRef]
  26. Antus, B.; Harnasi, G.; Drozdovszky, O.; Barta, I. Monitoring oxidative stress during chronic obstructive pulmonary disease exacerbations using malondialdehyde: MDA and COPD exacerbations. Respirology 2014, 19, 74–79. [Google Scholar] [CrossRef] [PubMed]
  27. Antczak, A.; Nowak, D.; Shariati, B.; Król, M.; Piasecka, G.; Kurmanowska, Z. Increased hydrogen peroxide and thiobarbituric acid-reactive products in expired breath condensate of asthmatic patients. Eur. Respir. J. 1997, 10, 1235–1241. [Google Scholar] [CrossRef] [PubMed]
  28. Araneda, O.F.; García, C.; Lagos, N.; Quiroga, G.B.; Cajigal, J.Y.; Salazar, M.P.; Behn, C. Lung oxidative stress as related to exercise and altitude. Lipid peroxidation evidence in exhaled breath condensate: A possible predictor of acute mountain sickness. Eur. J. Appl. Physiol. 2005, 95, 383–390. [Google Scholar] [CrossRef]
  29. Araneda, O.; Guevara, A.; Contreras, C.; Lagos, N.; Berral, F. Exhaled Breath Condensate Analysis after Long Distance Races. Int. J. Sports Med. 2012, 33, 955–961. [Google Scholar] [CrossRef]
  30. Araneda, O.F.; Urbina-Stagno, R.; Tuesta, M.; Haichelis, D.; Alvear, M.; Salazar, M.P.; García, C. Increase of pro-oxidants with no evidence of lipid peroxidation in exhaled breath condensate after a 10-km race in non-athletes. J. Physiol. Biochem. 2014, 70, 107–115. [Google Scholar] [CrossRef]
  31. Barregard, L.; Sällsten, G.; Andersson, L.; Almstrand, A.C.; Gustafson, P.; Andersson, M.; Olin, A.C. Experimental exposure to wood smoke: Effects on airway inflammation and oxidative stress. Occup. Environ. Med. 2008, 65, 319–324. [Google Scholar] [CrossRef]
  32. Bartoli, M.L.; Novelli, F.; Costa, F.; Malagrinò, L.; Melosini, L.; Bacci, E.; Cianchetti, S.; Dente, F.L.; Di Franco, A.; Vagaggini, B.; et al. Malondialdehyde in Exhaled Breath Condensate as a Marker of Oxidative Stress in Different Pulmonary Diseases. Mediat. Inflamm. 2011, 2011, 891752. [Google Scholar] [CrossRef]
  33. Brand, P.; Bischof, K.; Siry, L.; Bertram, J.; Schettgen, T.; Reisgen, U.; Kraus, T.; Gube, M. Exposure of healthy subjects with emissions from a gas metal arc welding process: Part 3—biological effect markers and lung function. Int. Arch. Occup. Environ. Health 2013, 86, 39–45. [Google Scholar] [CrossRef] [PubMed]
  34. Caglieri, A.; Goldoni, M.; Acampa, O.; Andreoli, R.; Vettori, M.V.; Corradi, M.; Apostoli, P.; Mutti, A. The Effect of Inhaled Chromium on Different Exhaled Breath Condensate Biomarkers among Chrome-Plating Workers. Environ. Health Perspect. 2006, 114, 542–546. [Google Scholar] [CrossRef] [PubMed]
  35. Casimirri, E.; Stendardo, M.; Bonci, M.; Andreoli, R.; Bottazzi, B.; Leone, R.; Schito, M.; Vaccari, A.; Papi, A.; Contoli, M.; et al. Biomarkers of oxidative-stress and inflammation in exhaled breath condensate from hospital cleaners. Biomarkers 2016, 21, 115–122. [Google Scholar] [CrossRef] [PubMed]
  36. Corradi, M.; Rubinstein, I.; Andreoli, R.; Manini, P.; Caglieri, A.; Poli, D.; Alinovi, R.; Mutti, A. Aldehydes in Exhaled Breath Condensate of Patients with Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. 2003, 167, 1380–1386. [Google Scholar] [CrossRef]
  37. Corradi, M.; Alinovi, R.; Goldoni, M.; Vettori, M.; Folesani, G.; Mozzoni, P.; Cavazzini, S.; Bergamaschi, E.; Rossi, L.; Mutti, A. Biomarkers of oxidative stress after controlled human exposure to ozone. Toxicol. Lett. 2002, 134, 219–225. [Google Scholar] [CrossRef]
  38. Corradi, M. Comparison between exhaled and sputum oxidative stress biomarkers in chronic airway inflammation. Eur. Respir. J. 2004, 24, 1011–1017. [Google Scholar] [CrossRef]
  39. Doruk, S.; Ozyurt, H.; Inonu, H.; Erkorkmaz, U.; Saylan, O.; Seyfikli, Z. Oxidative status in the lungs associated with tobacco smoke exposure. Clin. Chem. Lab. Med. 2011, 49, 2007–2012. Available online: https://www.degruyter.com/document/doi/10.1515/CCLM.2011.698/html (accessed on 30 March 2022). [CrossRef]
  40. Goldoni, M.; Catalani, S.; De Palma, G.; Manini, P.; Acampa, O.; Corradi, M.; Bergonzi, R.; Apostoli, P.; Mutti, A. Breath Condensate as a Suitable Matrix to Assess Lung Dose and Effects in Workers Exposed to Cobalt and Tungsten. Environ. Health Perspect. 2004, 112, 1293–1298. [Google Scholar] [CrossRef]
  41. Goldoni, M.; Corradi, M.; Mozzoni, P.; Folesani, G.; Alinovi, R.; Pinelli, S.; Andreoli, R.; Pigini, D.; Tillo, R.; Filetti, A.; et al. Concentration of exhaled breath condensate biomarkers after fractionated collection based on exhaled CO2 signal. J. Breath Res. 2013, 7, 017101. [Google Scholar] [CrossRef]
  42. Goldoni, M.; Caglieri, A.; Andreoli, R.; Poli, D.; Manini, P.; Vettori, M.V.; Corradi, M.; Mutti, A. Influence of condensation temperature on selected exhaled breath parameters. BMC Pulm. Med. 2005, 5, 10. [Google Scholar] [CrossRef]
  43. Gong, J.; Zhu, T.; Kipen, H.; Wang, G.; Hu, M.; Ohman-Strickland, P.; Lu, S.E.; Zhang, L.; Wang, Y.; Zhu, P.; et al. Malondialdehyde in exhaled breath condensate and urine as a biomarker of air pollution induced oxidative stress. J. Expo. Sci. Environ. Epidemiol. 2013, 23, 322–327. [Google Scholar] [CrossRef]
  44. Graczyk, H.; Lewinski, N.; Zhao, J.; Sauvain, J.J.; Suarez, G.; Wild, P.; Danuser, B.; Riediker, M. Increase in oxidative stress levels following welding fume inhalation: A controlled human exposure study. Part. Fibre Toxicol. 2015, 13, 31. [Google Scholar] [CrossRef] [PubMed]
  45. Gube, M.; Ebel, J.; Brand, P.; Göen, T.; Holzinger, K.; Reisgen, U.; Kraus, T. Biological effect markers in exhaled breath condensate and biomonitoring in welders: Impact of smoking and protection equipment. Int. Arch. Occup. Environ. Health 2010, 83, 803–811. [Google Scholar] [CrossRef] [PubMed]
  46. Inonu, H.; Doruk, S.; Sahin, S.; Erkorkmaz, U.; Celik, D.; Celikel, S.; Seyfikli, Z. Oxidative Stress Levels in Exhaled Breath Condensate Associated With COPD and Smoking. Respir. Care 2012, 57, 413–419. [Google Scholar] [CrossRef] [PubMed]
  47. Lärstad, M.; Ljungkvist, G.; Olin, A.-C.; Torén, K. Determination of malondialdehyde in breath condensate by high-performance liquid chromatography with fluorescence detection. J. Chromatogr. B 2002, 766, 107–114. [Google Scholar] [CrossRef]
  48. Laumbach, R.J.; Kipen, H.M.; Ko, S.; Kelly-McNeil, K.; Cepeda, C.; Pettit, A.; Ohman-Strickland, P.; Zhang, L.; Zhang, J.; Gong, J.; et al. A controlled trial of acute effects of human exposure to traffic particles on pulmonary oxidative stress and heart rate variability. Part. Fibre Toxicol. 2014, 11, 45. [Google Scholar] [CrossRef]
  49. Lee, J.S.; Choi, Y.C.; Shin, J.H.; Lee, J.H.; Lee, Y.; Park, S.Y.; Baek, J.E.; Park, J.D.; Ahn, K.; Yu, I.J. Health surveillance study of workers who manufacture multi-walled carbon nanotubes. Nanotoxicology 2015, 9, 802–811. [Google Scholar] [CrossRef]
  50. Majewska, E.; Kasielski, M.; Luczynski, R.; Bartosz, G.; Bialasiewicz, P.; Nowak, D. Elevated exhalation of hydrogen peroxide and thiobarbituric acid reactive substances in patients with community acquired pneumonia. Respir. Med. 2004, 98, 669–676. [Google Scholar] [CrossRef][Green Version]
  51. Nowak, D.; Kałucka, S.; Białasiewicz, P.; Król, M. Exhalation of H2O2 and thiobarbituric acid reactive substances (TBARs) by healthy subjects. Free Radic. Biol. Med. 2001, 30, 178–186. [Google Scholar] [CrossRef]
  52. Pelclova, D.; Zdimal, V.; Schwarz, J.; Dvorackova, S.; Komarc, M.; Ondracek, J.; Kostejn, M.; Kacer, P.; Vlckova, S.; Fenclova, Z.; et al. Markers of Oxidative Stress in the Exhaled Breath Condensate of Workers Handling Nanocomposites. Nanomaterials 2018, 8, 611. [Google Scholar] [CrossRef]
  53. Pelclová, D.; Fenclová, Z.; Vlčková, S.; Klusáčková, P.; Lebedová, J.; Syslová, K.; Běláček, J.; Kuzma, M.; Navrátil, T.; Zakharov, S. Occupational asthma follow-up—which markers are elevated in exhaled breath condensate and plasma? Int. J. Occup. Med. Environ. Health 2014, 27, 206–215. Available online: http://ijomeh.eu/Occupational-asthma-follow-up-Which-markers-are-elevated-in-exhaled-breath-condensate-and-plasma-,2044,0,2.html (accessed on 30 March 2022). [CrossRef] [PubMed]
  54. Pelclova, D.; Zdimal, V.; Kacer, P.; Fenclova, Z.; Vlckova, S.; Syslova, K.; Navratil, T.; Schwarz, J.; Zikova, N.; Barosova, H. Oxidative stress markers are elevated in exhaled breath condensate of workers exposed to nanoparticles during iron oxide pigment production. J. Breath Res. 2016, 10, 016004. [Google Scholar] [CrossRef]
  55. Riccelli, M.G.; Goldoni, M.; Andreoli, R.; Mozzoni, P.; Pinelli, S.; Alinovi, R.; Selis, L.; Mutti, A.; Corradi, M. Biomarkers of exposure to stainless steel tungsten inert gas welding fumes and the effect of exposure on exhaled breath condensate. Toxicol. Lett. 2018, 292, 108–114. [Google Scholar] [CrossRef] [PubMed]
  56. Rundell, K.W.; Slee, J.B.; Caviston, R.; Hollenbach, A.M. Decreased Lung Function After Inhalation of Ultrafine and Fine Particulate Matter During Exercise is Related to Decreased Total Nitrate in Exhaled Breath Condensate. Inhal. Toxicol. 2008, 20, 1–9. [Google Scholar] [CrossRef] [PubMed]
  57. Sakhvidi, M.J.; Biabani Ardekani, J.; Firoozichahak, A.; Zavarreza, J.; Hajaghazade, M.; Mostaghaci, M.; Mehrparvar, A.; Barkhordari, A. Exhaled breath malondialdehyde, spirometric results and dust exposure assessment in ceramics production workers. Int. J. Occup. Med. Environ. Health 2015, 28, 81–89. [Google Scholar] [CrossRef] [PubMed]
  58. Sauvain, J.-J.; Hohl, M.S.S.; Wild, P.; Pralong, J.A.; Riediker, M. Exhaled Breath Condensate as a Matrix for Combustion-Based Nanoparticle Exposure and Health Effect Evaluation. J. Aerosol Med. Pulm. Drug Deliv. 2014, 27, 449–458. [Google Scholar] [CrossRef] [PubMed]
  59. Stockfelt, L.; Sallsten, G.; Olin, A.C.; Almerud, P.; Samuelsson, L.; Johannesson, S.; Molnar, P.; Strandberg, B.; Almstrand, A.C.; Bergemalm-Rynell, K. Effects on airways of short-term exposure to two kinds of wood smoke in a chamber study of healthy humans. Inhal. Toxicol. 2012, 24, 47–59. [Google Scholar] [CrossRef]
  60. Syslová, K.; Kacer, P.; Kuzma, M.; Najmanová, V.; Fenclová, Z.; Vlcková, S.; Lebedová, J.; Pelclová, D. Rapid and easy method for monitoring oxidative stress markers in body fluids of patients with asbestos or silica-induced lung diseases. J. Chromatogr. B 2009, 877, 2477–2486. [Google Scholar] [CrossRef]
  61. Szkudlarek, U.; Maria, L.; Kasielski, M.; Kaucka, S.; Nowak, D. Exhaled hydrogen peroxide correlates with the release of reactive oxygen species by blood phagocytes in healthy subjects. Respir. Med. 2003, 97, 718–725. [Google Scholar] [CrossRef][Green Version]
  62. Tanger, S.R.O. (Ed.) Proceedings of the 10th Anniversary International Conference on Nanomaterials—Research and Application (NANOCON 2018), Brno, Czech Republic, 17–19 October 2018; Curran Associates: Red Hook, NY, USA, 2019; p. 741.
  63. Pinchuk, I.; Weber, D.; Kochlik, B.; Stuetz, W.; Toussaint, O.; Debacq-Chainiaux, F.; Dollé, M.E.T.; Jansen, E.H.J.M.; Gonos, E.S.; Sikora, E. Gender- and age-dependencies of oxidative stress, as detected based on the steady state concentrations of different biomarkers in the MARK-AGE study. Redox Biol. 2019, 24, 101204. [Google Scholar] [CrossRef]
  64. Caliri, A.W.; Tommasi, S.; Besaratinia, A. Relationships among smoking, oxidative stress, inflammation, macromolecular damage, and cancer. Mutat. Res./Rev. Mutat. Res. 2021, 787, 108365. [Google Scholar] [CrossRef] [PubMed]
  65. Lykkesfeldt, J. Malondialdehyde as biomarker of oxidative damage to lipids caused by smoking. Clin. Chim. Acta 2007, 380, 50–58. [Google Scholar] [CrossRef] [PubMed]
  66. Carraro, E.; Schilirò, T.; Biorci, F.; Romanazzi, V.; Degan, R.; Buonocore, D.; Verri, M.; Dossena, M.; Bonetta, S.; Gilli, G. Physical Activity, Lifestyle Factors and Oxidative Stress in Middle Age Healthy Subjects. Int. J. Environ. Res. Public Health 2018, 15, 1152. [Google Scholar] [CrossRef]
  67. Rosias, P. Methodological aspects of exhaled breath condensate collection and analysis. J. Breath Res. 2012, 6, 027102. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.